Synthetic peptide corresponding to Human GLP1 aa 1-19 conjugated to Bovine Serum Albumin (BSA) (Bis-diazotised tolidine (Bdt)). The mid to C terminal region of GLP 1 [1-19] enabling immunoreactivity with N terminal truncated and C terminally extended forms of GLP 1 (e.g. GLP 1[7 to 36]amide).
Our Abpromise guarantee covers the use of ab22625 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-Fr||Use at an assay dependent concentration.|
|IHC-P||Use at an assay dependent concentration.|
|IHC-R||Use at an assay dependent concentration.
Vibratome slices, All standard crosslinking agents may be used. 1/500 to 1/4000, using overnight incubation and peroxidase anti peroxidase procedure. 1/100 to 1/1000, using overnight incubation and indirect immunofluorescence procedure.
|ICC/IF||Use at an assay dependent concentration. Used at a dilution of 1/500 for 2 hrs using mouse small intestinal cells (see Abreview for further details).|
ab22625 at a 1/500 dilution staining mouse small intestine (pancreas) by ICC/IF. The cells were paraformaldehyde fixed and blocked with 5% serum prior to incubation with the antibody for 2 hours. Bound antibody was detected using a Cy2 conjugated donkey anti-rabbit IgG (H+L). As expected, the small intestine staining is in a very low number of entero-endocrine cells (L-cells), laying on the instestinal villi.
This image is courtesy of an Abreview.